|Articles|December 1, 2004
FDA grants Vitrase 5 years' exclusivity
The FDA has extended ISTA Pharmaceuticals' market exclusivity for hyaluronidase for injection (Vitrase) to 5 years from 3 years. The exclusivity will end May 5, 2009.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
2
Neurotrophic keratitis outcomes improve with early, stage-based care
3
Strategic approaches optimize teaching and learning in the clinic
4
Improved grading scales for oncology drugs causing ocular adverse events
5








































.png)


